請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/22499完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 蔡錦華 | |
| dc.contributor.author | Ju-Yin Lin | en |
| dc.contributor.author | 林如愔 | zh_TW |
| dc.date.accessioned | 2021-06-08T04:19:15Z | - |
| dc.date.copyright | 2010-09-09 | |
| dc.date.issued | 2010 | |
| dc.date.submitted | 2010-07-23 | |
| dc.identifier.citation | Acha-Orbea, H., and McDevitt, H. O. (1990). The role of class II molecules in development of insulin-dependent diabetes mellitus in mice, rats and humans. Curr Top Microbiol Immunol 156, 103-119.
Amon, W., and Farrell, P. J. (2005). Reactivation of Epstein-Barr virus from latency. Rev Med Virol 15, 149-156. Anderson, M. S., and Miller, J. (1992). Invariant chain can function as a chaperone protein for class II major histocompatibility complex molecules. Proc Natl Acad Sci U S A 89, 2282-2286. Acha-Orbea, H., and McDevitt, H. O. (1990). The role of class II molecules in development of insulin-dependent diabetes mellitus in mice, rats and humans. Curr Top Microbiol Immunol 156, 103-119. Amon, W., and Farrell, P. J. (2005). Reactivation of Epstein-Barr virus from latency. Rev Med Virol 15, 149-156. Anderson, M. S., and Miller, J. (1992). Invariant chain can function as a chaperone protein for class II major histocompatibility complex molecules. Proc Natl Acad Sci U S A 89, 2282-2286. Appay, V., Zaunders, J. J., Papagno, L., Sutton, J., Jaramillo, A., Waters, A., Easterbrook, P., Grey, P., Smith, D., McMichael, A. J., et al. (2002). Characterization of CD4(+) CTLs ex vivo. J Immunol 168, 5954-5958. Baer, R., Bankier, A. T., Biggin, M. D., Deininger, P. L., Farrell, P. J., Gibson, T. J., Hatfull, G., Hudson, G. S., Satchwell, S. C., Seguin, C., and et al. (1984). DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature 310, 207-211. Baumann, M. A., and Paul, C. C. (1992). Interleukin-5 is an autocrine growth factor for Epstein-Barr virus-transformed B lymphocytes. Blood 79, 1763-1767. Benschop, R. J., and Cambier, J. C. (1999). B cell development: signal transduction by antigen receptors and their surrogates. Curr Opin Immunol 11, 143-151. Boshoff, C., and Weiss, R. (2002). AIDS-related malignancies. Nat Rev Cancer 2, 373-382. Boss, J. M. (1997). Regulation of transcription of MHC class II genes. Curr Opin Immunol 9, 107-113. Boss, J. M., and Jensen, P. E. (2003). Transcriptional regulation of the MHC class II antigen presentation pathway. Curr Opin Immunol 15, 105-111. Brown, A. M., Barr, C. L., and Ting, J. P. (1991). Sequences homologous to class II MHC W, X, and Y elements mediate constitutive and IFN-gamma-induced expression of human class II-associated invariant chain gene. J Immunol 146, 3183-3189. Brown, A. M., Wright, K. L., and Ting, J. P. (1993). Human major histocompatibility complex class II-associated invariant chain gene promoter. Functional analysis and in vivo protein/DNA interactions of constitutive and IFN-gamma-induced expression. J Biol Chem 268, 26328-26333. Burdin, N., Peronne, C., Banchereau, J., and Rousset, F. (1993). Epstein-Barr virus transformation induces B lymphocytes to produce human interleukin 10. J Exp Med 177, 295-304. Burkhardt, A. L., Bolen, J. B., Kieff, E., and Longnecker, R. (1992). An Epstein-Barr virus transformation-associated membrane protein interacts with src family tyrosine kinases. J Virol 66, 5161-5167. Burkitt, D. (1962). A children's cancer dependent on climatic factors. Nature 194, 232-234. Burstein, H. J., Tepper, R. I., Leder, P., and Abbas, A. K. (1991). Humoral immune functions in IL-4 transgenic mice. J Immunol 147, 2950-2956. Caldwell, R. G., Brown, R. C., and Longnecker, R. (2000). Epstein-Barr virus LMP2A-induced B-cell survival in two unique classes of EmuLMP2A transgenic mice. J Virol 74, 1101-1113. Caldwell, R. G., Wilson, J. B., Anderson, S. J., and Longnecker, R. (1998). Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 9, 405-411. Cebulla, C. M., Miller, D. M., and Sedmak, D. D. (1999). Viral inhibition of interferon signal transduction. Intervirology 42, 325-330. Chang, Y., Lee, H. H., Chang, S. S., Hsu, T. Y., Wang, P. W., Chang, Y. S., Takada, K., and Tsai, C. H. (2004). Induction of Epstein-Barr virus latent membrane protein 1 by a lytic transactivator Rta. J Virol 78, 13028-13036. Chen, H., Ray-Gallet, D., Zhang, P., Hetherington, C. J., Gonzalez, D. A., Zhang, D. E., Moreau-Gachelin, F., and Tenen, D. G. (1995). PU.1 (Spi-1) autoregulates its expression in myeloid cells. Oncogene 11, 1549-1560. Chen, H., Zhang, P., Radomska, H. S., Hetherington, C. J., Zhang, D. E., and Tenen, D. G. (1996). Octamer binding factors and their coactivator can activate the murine PU.1 (spi-1) promoter. J Biol Chem 271, 15743-15752. Chen, S. Y., Lu, J., Shih, Y. C., and Tsai, C. H. (2002). Epstein-Barr virus latent membrane protein 2A regulates c-Jun protein through extracellular signal-regulated kinase. J Virol 76, 9556-9561. Chevallier-Greco, A., Manet, E., Chavrier, P., Mosnier, C., Daillie, J., and Sergeant, A. (1986). Both Epstein-Barr virus (EBV)-encoded trans-acting factors, EB1 and EB2, are required to activate transcription from an EBV early promoter. EMBO J 5, 3243-3249. Cho, M. S., Milman, G., and Hayward, S. D. (1985). A second Epstein-Barr virus early antigen gene in BamHI fragment M encodes a 48- to 50-kilodalton nuclear protein. J Virol 56, 860-866. Clough, W. (1979). Deoxyribonuclease activity found in Epstein--Barr virus producing lymphoblastoid cells. Biochemistry 18, 4517-4521. Consortium (1999). Complete sequence and gene map of a human major histocompatibility complex. The MHC sequencing consortium. Nature 401, 921-923. Countryman, J., and Miller, G. (1985). Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA. Proc Natl Acad Sci U S A 82, 4085-4089. de Waal Malefyt, R., Haanen, J., Spits, H., Roncarolo, M. G., te Velde, A., Figdor, C., Johnson, K., Kastelein, R., Yssel, H., and de Vries, J. E. (1991). Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 174, 915-924. Defrance, T., Carayon, P., Billian, G., Guillemot, J. C., Minty, A., Caput, D., and Ferrara, P. (1994). Interleukin 13 is a B cell stimulating factor. J Exp Med 179, 135-143. Denzin, L. K., and Cresswell, P. (1995). HLA-DM induces CLIP dissociation from MHC class II alpha beta dimers and facilitates peptide loading. Cell 82, 155-165. Dixon, A. M., Stanley, B. J., Matthews, E. E., Dawson, J. P., and Engelman, D. M. (2006). Invariant chain transmembrane domain trimerization: a step in MHC class II assembly. Biochemistry 45, 5228-5234. Dorothee, G., Vergnon, I., Menez, J., Echchakir, H., Grunenwald, D., Kubin, M., Chouaib, S., and Mami-Chouaib, F. (2002). Tumor-infiltrating CD4+ T lymphocytes express APO2 ligand (APO2L)/TRAIL upon specific stimulation with autologous lung carcinoma cells: role of IFN-alpha on APO2L/TRAIL expression and -mediated cytotoxicity. J Immunol 169, 809-817. Drexler, H. G. (1993). Recent results on the biology of Hodgkin and Reed-Sternberg cells. II. Continuous cell lines. Leuk Lymphoma 9, 1-25. Dykstra, M. L., Longnecker, R., and Pierce, S. K. (2001). Epstein-Barr virus coopts lipid rafts to block the signaling and antigen transport functions of the BCR. Immunity 14, 57-67. Engels, N., Merchant, M., Pappu, R., Chan, A. C., Longnecker, R., and Wienands, J. (2001). Epstein-Barr virus latent membrane protein 2A (LMP2A) employs the SLP-65 signaling module. J Exp Med 194, 255-264. Epstein, M. A., Achong, B. G., and Barr, Y. M. (1964). Virus Particles in Cultured Lymphoblasts from Burkitt's Lymphoma. Lancet 1, 702-703. Fields, B. N., Knipe, D. M., and Howley, P. M. (2007). Fields' virology, 5th edn (Philadelphia: Wolters kluwer/Lippincott Williams & Wilkins). Freisewinkel, I. M., Schenck, K., and Koch, N. (1993). The segment of invariant chain that is critical for association with major histocompatibility complex class II molecules contains the sequence of a peptide eluted from class II polypeptides. Proc Natl Acad Sci U S A 90, 9703-9706. Fruehling, S., Lee, S. K., Herrold, R., Frech, B., Laux, G., Kremmer, E., Grasser, F. A., and Longnecker, R. (1996). Identification of latent membrane protein 2A (LMP2A) domains essential for the LMP2A dominant-negative effect on B-lymphocyte surface immunoglobulin signal transduction. J Virol 70, 6216-6226. Fruehling, S., and Longnecker, R. (1997). The immunoreceptor tyrosine-based activation motif of Epstein-Barr virus LMP2A is essential for blocking BCR-mediated signal transduction. Virology 235, 241-251. Fruehling, S., Swart, R., Dolwick, K. M., Kremmer, E., and Longnecker, R. (1998). Tyrosine 112 of latent membrane protein 2A is essential for protein tyrosine kinase loading and regulation of Epstein-Barr virus latency. J Virol 72, 7796-7806. Fukayama, M., Hayashi, Y., Iwasaki, Y., Chong, J., Ooba, T., Takizawa, T., Koike, M., Mizutani, S., Miyaki, M., and Hirai, K. (1994). Epstein-Barr virus-associated gastric carcinoma and Epstein-Barr virus infection of the stomach. Lab Invest 71, 73-81. Fukuda, M., and Longnecker, R. (2004). Latent membrane protein 2A inhibits transforming growth factor-beta 1-induced apoptosis through the phosphatidylinositol 3-kinase/Akt pathway. J Virol 78, 1697-1705. Fukuda, M., and Longnecker, R. (2005). Epstein-Barr virus (EBV) latent membrane protein 2A regulates B-cell receptor-induced apoptosis and EBV reactivation through tyrosine phosphorylation. J Virol 79, 8655-8660. Germain, R. N. (1994). MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 76, 287-299. Ghosh, P., Amaya, M., Mellins, E., and Wiley, D. C. (1995). The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 378, 457-462. Glimcher, L. H., and Kara, C. J. (1992). Sequences and factors: a guide to MHC class-II transcription. Annu Rev Immunol 10, 13-49. Go, N. F., Castle, B. E., Barrett, R., Kastelein, R., Dang, W., Mosmann, T. R., Moore, K. W., and Howard, M. (1990). Interleukin 10, a novel B cell stimulatory factor: unresponsiveness of X chromosome-linked immunodeficiency B cells. J Exp Med 172, 1625-1631. Goodbourn, S., Didcock, L., and Randall, R. E. (2000). Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. J Gen Virol 81, 2341-2364. Gotoh, B., Komatsu, T., Takeuchi, K., and Yokoo, J. (2002). Paramyxovirus strategies for evading the interferon response. Rev Med Virol 12, 337-357. Greenspan, J. S., Greenspan, D., Lennette, E. T., Abrams, D. I., Conant, M. A., Petersen, V., and Freese, U. K. (1985). Replication of Epstein-Barr virus within the epithelial cells of oral 'hairy' leukoplakia, an AIDS-associated lesion. N Engl J Med 313, 1564-1571. Gregory, C. D., Dive, C., Henderson, S., Smith, C. A., Williams, G. T., Gordon, J., and Rickinson, A. B. (1991). Activation of Epstein-Barr virus latent genes protects human B cells from death by apoptosis. Nature 349, 612-614. Guardiola, J., and Maffei, A. (1993). Control of MHC class II gene expression in autoimmune, infectious, and neoplastic diseases. Crit Rev Immunol 13, 247-268. Hahn, S., and Erb, P. (1999). The immunomodulatory role of CD4-positive cytotoxic T-lymphocytes in health and disease. Int Rev Immunol 18, 449-464. Hake, S. B., Masternak, K., Kammerbauer, C., Janzen, C., Reith, W., and Steimle, V. (2000). CIITA leucine-rich repeats control nuclear localization, in vivo recruitment to the major histocompatibility complex (MHC) class II enhanceosome, and MHC class II gene transactivation. Mol Cell Biol 20, 7716-7725. Hardwick, J. M., Lieberman, P. M., and Hayward, S. D. (1988). A new Epstein-Barr virus transactivator, R, induces expression of a cytoplasmic early antigen. J Virol 62, 2274-2284. Hatfull, G., Bankier, A. T., Barrell, B. G., and Farrell, P. J. (1988). Sequence analysis of Raji Epstein-Barr virus DNA. Virology 164, 334-340. Hegde, N. R., Chevalier, M. S., and Johnson, D. C. (2003). Viral inhibition of MHC class II antigen presentation. Trends Immunol 24, 278-285. Heise, M. T., Connick, M., and Virgin, H. W. t. (1998). Murine cytomegalovirus inhibits interferon gamma-induced antigen presentation to CD4 T cells by macrophages via regulation of expression of major histocompatibility complex class II-associated genes. J Exp Med 187, 1037-1046. Henle, G., Henle, W., and Diehl, V. (1968). Relation of Burkitt's tumor-associated herpes-ytpe virus to infectious mononucleosis. Proc Natl Acad Sci U S A 59, 94-101. Henle, W., Hummeler, K., and Henle, G. (1966). Antibody coating and agglutination of virus particles separated from the EB3 line of Burkitt lymphoma cells. J Bacteriol 92, 269-271. Heslop, H. E., Brenner, M. K., and Rooney, C. M. (1994). Donor T cells to treat EBV-associated lymphoma. N Engl J Med 331, 679-680. Heslop, H. E., and Rooney, C. M. (1997). Adoptive cellular immunotherapy for EBV lymphoproliferative disease. Immunol Rev 157, 217-222. Hislop, A. D., Ressing, M. E., van Leeuwen, D., Pudney, V. A., Horst, D., Koppers-Lalic, D., Croft, N. P., Neefjes, J. J., Rickinson, A. B., and Wiertz, E. J. (2007). A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates. J Exp Med 204, 1863-1873. Hochberg, D., Middeldorp, J. M., Catalina, M., Sullivan, J. L., Luzuriaga, K., and Thorley-Lawson, D. A. (2004). Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo. Proc Natl Acad Sci U S A 101, 239-244. Hung, J. J., Wang, Y. T., and Chang, W. C. (2006). Sp1 deacetylation induced by phorbol ester recruits p300 to activate 12(S)-lipoxygenase gene transcription. Mol Cell Biol 26, 1770-1785. Ikeda, A., Caldwell, R. G., Longnecker, R., and Ikeda, M. (2003). Itchy, a Nedd4 ubiquitin ligase, downregulates latent membrane protein 2A activity in B-cell signaling. J Virol 77, 5529-5534. Ikeda, M., Ikeda, A., and Longnecker, R. (2001). PY motifs of Epstein-Barr virus LMP2A regulate protein stability and phosphorylation of LMP2A-associated proteins. J Virol 75, 5711-5718. Ikeda, M., Ikeda, A., and Longnecker, R. (2002). Lysine-independent ubiquitination of Epstein-Barr virus LMP2A. Virology 300, 153-159. Johnson, D. C., and Hegde, N. R. (2002). Inhibition of the MHC class II antigen presentation pathway by human cytomegalovirus. Curr Top Microbiol Immunol 269, 101-115. Kamal, M., Katira, A., and Gordon, J. (1991). Stimulation of B lymphocytes via CD72 (human Lyb-2). Eur J Immunol 21, 1419-1424. Kanazawa, S., Okamoto, T., and Peterlin, B. M. (2000). Tat competes with CIITA for the binding to P-TEFb and blocks the expression of MHC class II genes in HIV infection. Immunity 12, 61-70. Kaplan, M. J., Ray, D., Mo, R. R., Yung, R. L., and Richardson, B. C. (2000). TRAIL (Apo2 ligand) and TWEAK (Apo3 ligand) mediate CD4+ T cell killing of antigen-presenting macrophages. J Immunol 164, 2897-2904. Kaufman, J. F., Auffray, C., Korman, A. J., Shackelford, D. A., and Strominger, J. (1984). The class II molecules of the human and murine major histocompatibility complex. Cell 36, 1-13. Kelly, A. P., Monaco, J. J., Cho, S. G., and Trowsdale, J. (1991). A new human HLA class II-related locus, DM. Nature 353, 571-573. Kikuta, H., Taguchi, Y., Tomizawa, K., Kojima, K., Kawamura, N., Ishizaka, A., Sakiyama, Y., Matsumoto, S., Imai, S., Kinoshita, T., and et al. (1988). Epstein-Barr virus genome-positive T lymphocytes in a boy with chronic active EBV infection associated with Kawasaki-like disease. Nature 333, 455-457. Kim, O. J., and Yates, J. L. (1993). Mutants of Epstein-Barr virus with a selective marker disrupting the TP gene transform B cells and replicate normally in culture. J Virol 67, 7634-7640. Kindt, T. J., Goldsby, R. A., Osborne, B. A., and Kuby, J. (2007). Kuby immunology, 6th edn (New York: W.H. Freeman). Kjer-Nielsen, L., Perera, J. D., Boyd, L. F., Margulies, D. H., and McCluskey, J. (1990). The extracellular domains of MHC class II molecules determine their processing requirements for antigen presentation. J Immunol 144, 2915-2924. Klein, C., Lisowska-Grospierre, B., LeDeist, F., Fischer, A., and Griscelli, C. (1993). Major histocompatibility complex class II deficiency: clinical manifestations, immunologic features, and outcome. J Pediatr 123, 921-928. Lamb, C. A., and Cresswell, P. (1992). Assembly and transport properties of invariant chain trimers and HLA-DR-invariant chain complexes. J Immunol 148, 3478-3482. Laux, G., Economou, A., and Farrell, P. J. (1989). The terminal protein gene 2 of Epstein-Barr virus is transcribed from a bidirectional latent promoter region. J Gen Virol 70 ( Pt 11), 3079-3084. Laux, G., Perricaudet, M., and Farrell, P. J. (1988). A spliced Epstein-Barr virus gene expressed in immortalized lymphocytes is created by circularization of the linear viral genome. EMBO J 7, 769-774. LeibundGut-Landmann, S., Waldburger, J. M., Krawczyk, M., Otten, L. A., Suter, T., Fontana, A., Acha-Orbea, H., and Reith, W. (2004). Mini-review: Specificity and expression of CIITA, the master regulator of MHC class II genes. Eur J Immunol 34, 1513-1525. Levitskaya, J., Coram, M., Levitsky, V., Imreh, S., Steigerwald-Mullen, P. M., Klein, G., Kurilla, M. G., and Masucci, M. G. (1995). Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375, 685-688. Levitskaya, J., Sharipo, A., Leonchiks, A., Ciechanover, A., and Masucci, M. G. (1997). Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc Natl Acad Sci U S A 94, 12616-12621. Li, D., Qian, L., Chen, C., Shi, M., Yu, M., Hu, M., Song, L., Shen, B., and Guo, N. (2009). Down-regulation of MHC class II expression through inhibition of CIITA transcription by lytic transactivator Zta during Epstein-Barr virus reactivation. J Immunol 182, 1799-1809. Longan, L., and Longnecker, R. (2000). Epstein-Barr virus latent membrane protein 2A has no growth-altering effects when expressed in differentiating epithelia. J Gen Virol 81, 2245-2252. Longnecker, R., Druker, B., Roberts, T. M., and Kieff, E. (1991). An Epstein-Barr virus protein associated with cell growth transformation interacts with a tyrosine kinase. J Virol 65, 3681-3692. Longnecker, R., Merchant, M., Brown, M. E., Fruehling, S., Bickford, J. O., Ikeda, M., and Harty, R. N. (2000). WW- and SH3-domain interactions with Epstein-Barr virus LMP2A. Exp Cell Res 257, 332-340. Longnecker, R., Miller, C. L., Miao, X. Q., Marchini, A., and Kieff, E. (1992). The only domain which distinguishes Epstein-Barr virus latent membrane protein 2A (LMP2A) from LMP2B is dispensable for lymphocyte infection and growth transformation in vitro; LMP2A is therefore nonessential. J Virol 66, 6461-6469. Longnecker, R., Miller, C. L., Tomkinson, B., Miao, X. Q., and Kieff, E. (1993). Deletion of DNA encoding the first five transmembrane domains of Epstein-Barr virus latent membrane proteins 2A and 2B. J Virol 67, 5068-5074. Loughlin, A. J., Woodroofe, M. N., and Cuzner, M. L. (1993). Modulation of interferon-gamma-induced major histocompatibility complex class II and Fc receptor expression on isolated microglia by transforming growth factor-beta 1, interleukin-4, noradrenaline and glucocorticoids. Immunology 79, 125-130. Lu, J., Lin, W. H., Chen, S. Y., Longnecker, R., Tsai, S. C., Chen, C. L., and Tsai, C. H. (2006). Syk tyrosine kinase mediates Epstein-Barr virus latent membrane protein 2A-induced cell migration in epithelial cells. J Biol Chem 281, 8806-8814. Luka, J., Kallin, B., and Klein, G. (1979). Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate. Virology 94, 228-231. Mach, B., Steimle, V., and Reith, W. (1994). MHC class II-deficient combined immunodeficiency: a disease of gene regulation. Immunol Rev 138, 207-221. Macsween, K. F., and Crawford, D. H. (2003). Epstein-Barr virus-recent advances. Lancet Infect Dis 3, 131-140. Marechal, V., Dehee, A., Chikhi-Brachet, R., Piolot, T., Coppey-Moisan, M., and Nicolas, J. C. (1999). Mapping EBNA-1 domains involved in binding to metaphase chromosomes. J Virol 73, 4385-4392. Masternak, K., Muhlethaler-Mottet, A., Villard, J., Zufferey, M., Steimle, V., and Reith, W. (2000). CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex. Genes Dev 14, 1156-1166. Matskova, L., Ernberg, I., Pawson, T., and Winberg, G. (2001). C-terminal domain of the Epstein-Barr virus LMP2A membrane protein contains a clustering signal. J Virol 75, 10941-10949. Matza, D., Wolstein, O., Dikstein, R., and Shachar, I. (2001). Invariant chain induces B cell maturation by activating a TAF(II)105-NF-kappaB-dependent transcription program. J Biol Chem 276, 27203-27206. Menezes, J., Leibold, W., Klein, G., and Clements, G. (1975). Establishment and characterization of an Epstein-Barr virus (EBC)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma. Biomedicine 22, 276-284. Merchant, M., Caldwell, R. G., and Longnecker, R. (2000). The LMP2A ITAM is essential for providing B cells with development and survival signals in vivo. J Virol 74, 9115-9124. Miller, C. L., Burkhardt, A. L., Lee, J. H., Stealey, B., Longnecker, R., Bolen, J. B., and Kieff, E. (1995). Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. Immunity 2, 155-166. Miller, C. L., Lee, J. H., Kieff, E., Burkhardt, A. L., Bolen, J. B., and Longnecker, R. (1994a). Epstein-Barr virus protein LMP2A regulates reactivation from latency by negatively regulating tyrosine kinases involved in sIg-mediated signal transduction. Infect Agents Dis 3, 128-136. Miller, C. L., Lee, J. H., Kieff, E., and Longnecker, R. (1994b). An integral membrane protein (LMP2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin crosslinking. Proc Natl Acad Sci U S A 91, 772-776. Miller, C. L., Longnecker, R., and Kieff, E. (1993). Epstein-Barr virus latent membrane protein 2A blocks calcium mobilization in B lymphocytes. J Virol 67, 3087-3094. Miller, G., and Lipman, M. (1973). Release of infectious Epstein-Barr virus by transformed marmoset leukocytes. Proc Natl Acad Sci U S A 70, 190-194. Moody, C. A., Scott, R. S., Amirghahari, N., Nathan, C. O., Young, L. S., Dawson, C. W., and Sixbey, J. W. (2005). Modulation of the cell growth regulator mTOR by Epstein-Barr virus-encoded LMP2A. J Virol 79, 5499-5506. Moore, K. W., de Waal Malefyt, R., Coffman, R. L., and O'Garra, A. (2001). Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19, 683-765. Moore, K. W., Vieira, P., Fiorentino, D. F., Trounstine, M. L., Khan, T. A., and Mosmann, T. R. (1990). Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. Science 248, 1230-1234. Morris, P., Shaman, J., Attaya, M., Amaya, M., Goodman, S., Bergman, C., Monaco, J. J., and Mellins, E. (1994). An essential role for HLA-DM in antigen presentation by class II major histocompatibility molecules. Nature 368, 551-554. Morrison, J. A., Klingelhutz, A. J., and Raab-Traub, N. (2003). Epstein-Barr virus latent membrane protein 2A activates beta-catenin signaling in epithelial cells. J Virol 77, 12276-12284. Morrison, J. A., and Raab-Traub, N. (2005). Roles of the ITAM and PY motifs of Epstein-Barr virus latent membrane protein 2A in the inhibition of epithelial cell differentiation and activation of {beta}-catenin signaling. J Virol 79, 2375-2382. Muhlethaler-Mottet, A., Otten, L. A., Steimle, V., and Mach, B. (1997). Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. EMBO J 16, 2851-2860. Mullen, M. M., Haan, K. M., Longnecker, R., and Jardetzky, T. S. (2002). Structure of the Epstein-Barr virus gp42 protein bound to the MHC class II receptor HLA-DR1. Mol Cell 9, 375-385. Murphy, K., Travers, P., Walport, M., and Janeway, C. (2008). Janeway's immunobiology, 7th edn (New York: Garland Science). Neefjes, J. J., Momburg, F., and Hammerling, G. J. (1993). Selective and ATP-dependent translocation of peptides by the MHC-encoded transporter. Science 261, 769-771. Nonoyama, M., and Pagano, J. S. (1973). Homology between Epstein-Barr virus DNA and viral DNA from Burkitt's lymphoma and nasopharyngeal carcinoma determined by DNA-DNA reassociation kinetics. Nature 242, 44-47. O'Sullivan, D. M., Noonan, D., and Quaranta, V. (1987). Four Ia invariant chain forms derive from a single gene by alternate splicing and alternate initiation of transcription/translation. J Exp Med 166, 444-460. Paglia, P., Girolomoni, G., Robbiati, F., Granucci, F., and Ricciardi-Castagnoli, P. (1993). Immortalized dendritic cell line fully competent in antigen presentation initiates primary T cell responses in vivo. J Exp Med 178, 1893-1901. Paludan, C., Bickham, K., Nikiforow, S., Tsang, M. L., Goodman, K., Hanekom, W. A., Fonteneau, J. F., Stevanovic, S., and Munz, C. (2002). Epstein-Barr nuclear antigen 1-specific CD4(+) Th1 cells kill Burkitt's lymphoma cells. J Immunol 169, 1593-1603. Paludan, C., Schmid, D., Landthaler, M., Vockerodt, M., Kube, D., Tuschl, T., and Munz, C. (2005). Endogenous MHC class II processing of a viral nuclear antigen after autophagy. Science 307, 593-596. Panousis, C. G., and Rowe, D. T. (1997). Epstein-Barr virus latent membrane protein 2 associates with and is a substrate for mitogen-activated protein kinase. J Virol 71, 4752-4760. Pawson, T., and Gish, G. D. (1992). SH2 and SH3 domains: from structure to function. Cell 71, 359-362. Pegtel, D. M., Subramanian, A., Sheen, T. S., Tsai, C. H., Golub, T. R., and Thorley-Lawson, D. A. (2005). Epstein-Barr-virus-encoded LMP2A induces primary epithelial cell migration and invasion: possible role in nasopharyngeal carcinoma metastasis. J Virol 79, 15430-15442. Peng, M., and Lundgren, E. (1992). Transient expression of the Epstein-Barr virus LMP1 gene in human primary B cells induces cellular activation and DNA synthesis. Oncogene 7, 1775-1782. Portis, T., Dyck, P., and Longnecker, R. (2003). Epstein-Barr Virus (EBV) LMP2A induces alterations in gene transcription similar to those observed in Reed-Sternberg cells of Hodgkin lymphoma. Blood 102, 4166-4178. Portis, T., and Longnecker, R. (2003). Epstein-Barr virus LMP2A interferes with global transcription factor regulation when expressed during B-lymphocyte development. J Virol 77, 105-114. Portis, T., and Longnecker, R. (2004a). Epstein-Barr virus (EBV) LMP2A alters normal transcriptional regulation following B-cell receptor activation. Virology 318, 524-533. Portis, T., and Longnecker, R. (2004b). Epstein-Barr virus (EBV) LMP2A mediates B-lymphocyte survival through constitutive activation of the Ras/PI3K/Akt pathway. Oncogene 23, 8619-8628. Raab-Traub, N., and Flynn, K. (1986). The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell 47, 883-889. Rakoff-Nahoum, S., Chen, H., Kraus, T., George, I., Oei, E., Tyorkin, M., Salik, E., Beuria, P., and Sperber, K. (2001). Regulation of class II expression in monocytic cells after HIV-1 infection. J Immunol 167, 2331-2342. Reith, W., LeibundGut-Landmann, S., and Waldburger, J. M. (2005). Regulation of MHC class II gene expression by the class II transactivator. Nat Rev Immunol 5, 793-806. Reith, W., and Mach, B. (2001). The bare lymphocyte syndrome and the regulation of MHC expression. Annu Rev Immunol 19, 331-373. Ressing, M. E., Horst, D., Griffin, B. D., Tellam, J., Zuo, J., Khanna, R., Rowe, M., and Wiertz, E. J. (2008). Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products. Semin Cancer Biol 18, 397-408. Ressing, M. E., Keating, S. E., van Leeuwen, D., Koppers-Lalic, D., Pappworth, I. Y., Wiertz, E. J., and Rowe, M. (2005). Impaired transporter associated with antigen processing-dependent peptide transport during productive EBV infection. J Immunol 174, 6829-6838. Ressing, M. E., van Leeuwen, D., Verreck, F. A., Gomez, R., Heemskerk, B., Toebes, M., Mullen, M. M., Jardetzky, T. S., Longnecker, R., Schilham, M. W., et al. (2003). Interference with T cell receptor-HLA-DR interactions by Epstein-Barr virus gp42 results in reduced T helper cell recognition. Proc Natl Acad Sci U S A 100, 11583-11588. Rickinson, A. B., and Moss, D. J. (1997). Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol 15, 405-431. Roche, P. A., Marks, M. S., and Cresswell, P. (1991). Formation of a nine-subunit complex by HLA class II glycoproteins and the invariant chain. Nature 354, 392-394. Rochford, R., Miller, C. L., Cannon, M. J., Izumi, K. M., Kieff, E., and Longnecker, R. (1997). In vivo growth of Epstein-Barr virus transformed B cells with mutations in latent membrane protein 2 (LMP2). Arch Virol 142, 707-720. Rowe, D. T., Rowe, M., Evan, G. I., Wallace, L. E., Farrell, P. J., and Rickinson, A. B. (1986). Restricted expression of EBV latent genes and T-lymphocyte-detected membrane antigen in Burkitt's lymphoma cells. EMBO J 5, 2599-2607. Rowe, M., Glaunsinger, B., van Leeuwen, D., Zuo, J., Sweetman, D., Ganem, D., Middeldorp, J., Wiertz, E. J., and Ressing, M. E. (2007). Host shutoff during productive Epstein-Barr virus infection is mediated by BGLF5 and may contribute to immune evasion. Proc Natl Acad Sci U S A 104, 3366-3371. Rowe, M., Rowe, D. T., Gregory, C. D., Young, L. S., Farrell, P. J., Rupani, H., and Rickinson, A. B. (1987). Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J 6, 2743-2751. Sallusto, F., and Lanzavecchia, A. (1994). Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 179, 1109-1118. Sample, J., Liebowitz, D., and Kieff, E. (1989). Two related Epstein-Barr virus membrane proteins are encoded by separate genes. J Virol 63, 933-937. Santos-Argumedo, L., Gordon, J., Heath, A. W., and Howard, M. (1994). Antibodies to murine CD40 protect normal and malignant B cells from induced growth arrest. Cell Immunol 156, 272-285. Scala, G., Ferrara, F., Pastore, T., Alfinito, F., Pizzano, R., Corbo, L., and Venuta, S. (1987). Autocrine growth function of interleukin-1-like molecules secreted by neoplastic human B cells. Adv Exp Med Biol 213, 115-124. Scholle, F., Bendt, K. M., and Raab-Traub, N. (2000). Epstein-Barr virus LMP2A transforms epithelial cells, inhibits cell differentiation, and activates Akt. J Virol 74, 10681-10689. Scholle, F., Longnecker, R., and Raab-Traub, N. (1999). Epithelial cell adhesion to extracellular matrix proteins induces tyrosine phosphorylation of the Epstein-Barr virus latent membrane protein 2: a role for C-terminal Src kinase. J Virol 73, 4767-4775. Scholle, F., Longnecker, R., and Raab-Traub, N. (2001). Analysis of the phosphorylation status of Epstein-Barr virus LMP2A in epithelial cells. Virology 291, 208-214. Shimizu, N., Tanabe-Tochikura, A., Kuroiwa, Y., and Takada, K. (1994). Isolation of Epstein-Barr virus (EBV)-negative cell clones from the EBV-positive Burkitt's lymphoma (BL) line Akata: malignant phenotypes of BL cells are dependent on EBV. J Virol 68, 6069-6073. Si | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/22499 | - |
| dc.description.abstract | 藉由第二型主要組織相容性複合體(MHC class II)呈現外來抗原讓CD4+ T 細胞辨識，為免疫系統產生專一性免疫反應之重要機制，MHC class II 之表現量直接關係著T 淋巴細胞的活化，活化的CD4+ T 細胞能分泌抑制病毒感染之細胞激素並且協調免疫系統對抗病毒入侵。然而病毒可透過至少兩種方式逃離CD4+ T 細胞之偵測，一是抑制MHC class II 基因群之表現，另一是阻擾第二型抗原呈現之機轉。
EB 病毒感染全球超過92%的人口，為具有致癌性的疱疹病毒，可使B 細胞轉形為不朽化之淋巴母細胞株 (Lymphoblastoid cell lines)。目前研究發現，EB 病毒感染宿主細胞後，表現多種基因產物能干擾第一型抗原呈現的機制，以利長期潛伏宿主細胞中。以此作為模式系統發現，EB 病毒存在的情況下，第二型複合體(MHC class II)的蛋白質及RNA 表現量都受到抑制，已知第二型複合體也能呈現內生性病毒抗原，引發輔助T 細胞的抗病毒免疫功能，故選作進一步研究的對象，釐清EB 病毒干擾第二型抗原呈現的機制。結果顯示EB 病毒潛伏期膜蛋白LMP2A 具有抑制MHC class II 與CIITA 表現的能力，同時也觀察到CIITA 之轉錄因子PU.1 也受LMP2A 抑制之現象。利用LMP2A 之突變株，我們發現LMP2A 之ITAM motif 對此抑制功能是重要的，另一方面，也以單股核酸序列剔除淋巴母細胞株中LMP2A 之表現，發現MHC class II、CD74、CIITA 以及PU.1之表現量都有回升之情形，顯示LMP2A 抑制MHC class II 基因表現之路徑可能透過PU.1 與CIITA 之轉錄調控。 | zh_TW |
| dc.description.abstract | The presentation of peptides to CD4+ T cells by MHC class II molecules is of critical importance in specific recognition to a pathogen by the immune system. The level of MHC class II directly influences T lymphocyte activation. Activated CD4+ T cells can produce antiviral cytokines or co-ordinate antiviral immune responses. Viruses escape detection by CD4+ T cells by at least two mechanisms, inhibiting the expression of MHC class II genes and the antigen presentation pathway.
Epstein-Barr virus (EBV) is an oncogenic gamma-herpesvirus that persistently infects over 92% of the human population. The previous studies have shown that several EBV-encoded gene products can disrupt MHC class II function. Using EBV- immortalized B cells (lymphoblastoid cell line) as model system, we found that the expression of MHC class II is repressed in the present of EBV. The aim of this study was to identify the possible mechanisms of the down-regulation of MHC class II expression by EBV. The data in the present study demonstrated that ectopic expression of LMP2A can inhibit the constitutive expression of MHC class II and CIITA in B cell lines. The down-regulated mRNA level of MHC class II and CIITA was correlated to the suppressed level of PU.1, one of the transcription factors of CIITA, in the present of LMP2A. With LMP2A mutant constructs, we displayed that the ITAM motif could be responsible for the repression effect on MHC class II expression. On the other hand, by si-LMP2A expression in LCLs, we found the expression levels of MHC class II, CD74, CIITA and PU.1 were reversed. Taking together, LMP2A might suppress MHC class II expression through PU.1-CIITA pathway, and the ITAM motif on N-terminal tail of LMP2A could be responsible for it. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-08T04:19:15Z (GMT). No. of bitstreams: 1 ntu-99-R97445120-1.pdf: 2579865 bytes, checksum: d7777df1a2a027e97d7f9d7d1399e29f (MD5) Previous issue date: 2010 | en |
| dc.description.tableofcontents | 致謝…………………………………………………………I
中文摘要……………………………………………………II 英文摘要 .…………………………………………………III 序論 …………………………………………………………1 實驗目的 ……………………………………………………18 材料與方法 …………………………………………………19 結果…………………………………………………………37 討論…………………………………………………………45 表……………………………………………………………52 圖……………………………………………………………55 附錄…………………………………………………………84 參考文獻……………………………………………………90 | |
| dc.language.iso | zh-TW | |
| dc.title | EB病毒膜蛋白LMP2A抑制人類第二型主要組織相容性複合體基因表現之探討 | zh_TW |
| dc.title | Down-regulation of Human MHC Class II by Epstein-Barr virus Latent Membrane Protein 2A | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 98-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 許翠瑛,林素珍 | |
| dc.subject.keyword | EB病毒,第二型主要組織相容性複合體, | zh_TW |
| dc.subject.keyword | EBV,LMP2A,MHC class II,CIITA,PU.1, | en |
| dc.relation.page | 105 | |
| dc.rights.note | 未授權 | |
| dc.date.accepted | 2010-07-23 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 微生物學研究所 | zh_TW |
| 顯示於系所單位： | 微生物學科所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-99-1.pdf 目前未授權公開取用 | 2.52 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。